Bioneer Corporation

A064550

KR7064550007

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 12/05/2024 BST			5-day change	1st Jan Change
30,400 ^KRW	+0.16%		+1.67%	-8.71%

03-20	Bioneer Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	AFCAGRO Biotech Limited Enters into an Agreement with Bioneer Corporation to Produce Molecular Diagnostic Kits	CI

Bioneer Corporation announced that it has received KRW 20 billion in funding from a group of investors

October 30, 2019

On October 31, 2019, Bioneer Corporation closed the transaction.

Latest news about Bioneer Corporation

Bioneer Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
AFCAGRO Biotech Limited Enters into an Agreement with Bioneer Corporation to Produce Molecular Diagnostic Kits	12-13	CI
Bioneer Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Bioneer Corporation announced that it has received KRW 999.989452 million in funding from IBK Capital Corporation	20/05/20	CI
Bioneer Corporation announced that it expects to receive KRW 999.989452 million in funding from IBK Capital Corporation	19/05/20	CI
Bioneer Corporation announced that it has received KRW 20 billion in funding from a group of investors	30/10/19	CI
Bioneer Corporation announced that it expects to receive KRW 20 billion in funding from a group of investors	27/10/19	CI
Bioneer Corporation(KOSDAQ:A064550) added to S&P Global BMI Index	24/09/18	CI
Bioneer Corporation announced that it has received KRW 18.499955 billion in funding	25/04/18	CI
Bioneer Corporation announced that it expects to receive KRW 18.499955 billion in funding	16/04/18	CI
Bioneer Corporation(KOSDAQ:A064550) dropped from S&P Global BMI Index	18/09/17	CI
Bioneer Corporation announced that it has received KRW 4.9000392 billion in funding from GK Asset Co.,Ltd.	17/10/16	CI
Bioneer Corporation announced that it expects to receive KRW 4.9000392 billion in funding from GK Asset Co.,Ltd.	13/10/16	CI
Bioneer Corporation(KOSDAQ:A064550) added to S&P Global BMI Index	19/09/16	CI
Bioneer Corporation announced that it has received KRW 5 billion in funding from LB Investment Inc., KDB Capital Corporation, Investment Arm, IBK Capital Corporation, Anda Investment Partners, and another investor.	03/04/14	CI
Bioneer Corporation announced that it expects to receive KRW 5 billion in funding from LB Investment Inc., KDB Capital Corporation, Investment Arm, IBK Capital Corporation, Anda Investment Partners, and another investor.	01/04/14	CI

BIONEER CORPORATION is a Korea-based company engaged in the biotechnology business. The Company mainly focuses on the development of deoxyribonucleic acid (DNA) reagents, molecular diagnostic kits and other services, such as DNA and ribonucleic acid (RNA) amplification products, Oligo synthesis and reagents, gene synthesis services, gene expressions, protein expressions and purifications, genomics services, human diagnostics kits, veterinary diagnostics kits and others. It also provides DNA devices, including DNA extraction, amplification and quantitative analysis devices and other DNA diagnostic devices, and supplies for tests and others. In addition, it provides equipment and supplies used for biotechnology research. The Company operates its business within domestic market and in overseas markets, including America, China, Japan, India, Africa and others.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIONEER CORPORATION	-8.71%	572M
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	109B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-0.38%	22.25B
BIONTECH SE	-12.15%	22.09B
GENMAB A/S	-7.66%	18.68B
WUXI APPTEC CO., LTD.	-36.52%	17.58B
BEIGENE, LTD.	-10.09%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.46B

Bio Therapeutic Drugs